Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment...

Built on Insights from Patients and Caregivers, the New Website Curates Trusted Resources from Leading Organizations in Kidney Cancer NUTLEY, N.J., Feb. 26, 2026 /PRNewswire/ -- Eisai Inc....

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA...

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat...

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of...

Five-year survival data from pivotal Phase 3 Study 309/KEYNOTE-775 trial evaluating lenvatinib plus pembrolizumab in certain patients with advanced endometrial carcinoma Efficacy outcomes in...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today...

New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and...

Multiple endometrial carcinoma abstracts to be presented, including long-term follow-up data for lenvatinib plus pembrolizumab in advanced disease from Study 309/KEYNOTE-775 Final bone metastases...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody,...

E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1 TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this...

A link has been updated in this news release, FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease, issued...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer's disease, their care partners and healthcare professionals, with...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease 56% of Patients with Low Tau Continued to Demonstrate...

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Long-Term Follow-Up Data from LEAP-002 Offers Insights into Hepatocellular Carcinoma Treatment Pipeline Data in Endometrial Carcinoma Among Studies to be Presented NUTLEY, N.J., May 20, 2025...

Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for...

FOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGION In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD)...

- 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group - Clinical Data and Biomarkers Show...